Table 5. Survival analysis by stratified group adjusted for patient features and histology (n=28 997).
| Years | Number of patients (n) | Proportion of adenocarcinomas (%) | HR (95% CI)a | Annual HR (95% CI)a | HR (95% CI)b | Annual HR (95% CI)b |
|---|---|---|---|---|---|---|
|
Group 1 = PS 0/1/2 and stage IA–IIB | ||||||
| 2004/2005 | 625 | 38.5 | 1 | 1 | ||
| 2006 | 600 | 39.8 | 0.99 (0.86–1.14) | 0.99 (0.86–1.14) | ||
| 2007 | 884 | 42 | 0.93 (0.81–1.06) | 0.93 (0.82–1.06) | ||
| 2008 | 1148 | 46.9 | 0.85 (0.75–0.97) | 0.96 (0.94–0.99) | 0.86 (0.76–0.98) | 0.96 (0.94–0.99) |
| 2009 | 1865 | 49 | 0.71 (0.63–0.81) | 0.72 (0.64–0.82) | ||
| 2010 |
2256 |
52.2 |
0.72 (0.63–0.83) |
|
0.74 (0.65–0.85) |
|
|
Group 2 = PS 0/1/2 and stage IIIA | ||||||
| 2004/2005 | 263 | 34.6 | 1 | 1 | ||
| 2006 | 266 | 29.7 | 0.98 (0.82–1.18) | 0.97 (0.81–1.17) | ||
| 2007 | 354 | 33.3 | 1.03 (0.87–1.22) | 0.98 (0.95–1.00) | 1.02 (0.86–1.22) | 0.98 (0.95–1.01) |
| 2008 | 486 | 34.1 | 1.01 (0.86–1.20) | 1.01 (0.86–1.19) | ||
| 2009 | 731 | 35.2 | 0.92 (0.79–1.08) | 0.92 (0.79–1.08) | ||
| 2010 |
1159 |
39.8 |
0.90 (0.77–1.05) |
|
0.90 (0.77–1.05) |
|
|
Group 3 = PS 0/1/2 and stage IIIB | ||||||
| 2004/2005 | 464 | 33.8 | 1 | 1 | ||
| 2006 | 476 | 36.7 | 0.98 (0.86–1.12) | 0.98 (0.86–1.12) | ||
| 2007 | 615 | 36 | 0.95 (0.84–1.08) | 0.99 (0.97–1.01) | 0.95 (0.84–1.08) | 0.99 (0.97–1.01) |
| 2008 | 833 | 39.3 | 0.86 (0.77–0.97) | 0.86 (0.77–0.97) | ||
| 2009 | 1188 | 34.6 | 0.87 (0.78–0.98) | 0.87 (0.78–0.98) | ||
| 2010 |
1063 |
34.9 |
0.90 (0.79–1.01) |
|
0.90 (0.79–1.01) |
|
|
Group 4 = PS 3/4 and stage IA–IIIA | ||||||
| 2004/2005 | 59 | 15.2 | 1 | 1 | ||
| 2006 | 49 | 24.4 | 1.13 (0.75–1.69) | 1.13 (0.75–1.68) | ||
| 2007 | 74 | 33.7 | 1.08 (0.75–1.56) | 1.00 (0.94–1.06) | 1.09 (0.75–1.57) | 1.00 (0.94–1.06) |
| 2008 | 113 | 24.7 | 1.06 (0.75–1.48) | 1.05 (0.75–1.48) | ||
| 2009 | 152 | 32.2 | 0.99 (0.71–1.37) | 0.99 (0.71–1.38) | ||
| 2010 |
224 |
22.3 |
1.20 (0.88–1.65) |
|
1.20 (0.88–1.65) |
|
|
Group 5 = PS 0–4, stage IV and PS 3/4 stage IIIB | ||||||
| 2004/2005 | 1060 | 52.8 | 1 | 1 | ||
| 2006 | 1036 | 51.4 | 1.02 (0.93–1.11) | 1.02 (0.93–1.11) | ||
| 2007 | 1449 | 54.7 | 1.01 (0.93–1.09) | 0.99 (0.98–1.01) | 1.01 (0.93–1.09) | 1.00 (0.98–1.01) |
| 2008 | 2094 | 56.3 | 1.06 (0.99–1.15) | 1.07 (0.99–1.15) | ||
| 2009 | 3196 | 60.9 | 1.00 (0.93–1.07) | 1.00 (0.93–1.08) | ||
| 2010 | 4215 | 62.4 | 1.05 (0.97–1.12) | 1.05 (0.98–1.13) | ||
Abbreviations: CI=confidence interval; HR=hazard ratio; PS=performance status.
a
Hazard ratios adjusted for sex, age, ethnicity, co-morbidity and source of referral.
b
Hazard ratios adjusted for sex, age, ethnicity, co-morbidity, source of referral and histology (adenocarcinomas vs squamous cell carcinomas).